3
Clinical Trials associated with SNC-109一项在复发胶质母细胞瘤受试者中评估SNC109注射液的安全性、耐受性和药代动力学的I期临床研究
[Translation] A Phase I clinical study evaluating the safety, tolerability and pharmacokinetics of SNC109 injection in subjects with recurrent glioblastoma
一项在复发胶质母细胞瘤受试者中评估SNC109注射液的安全性、耐受性和药代动力学的I期临床研究
[Translation] A Phase I clinical study evaluating the safety, tolerability and pharmacokinetics of SNC109 injection in subjects with recurrent glioblastoma
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SNC109 in Patients With Recurrent Glioblastoma
A phase I study to evaluate the safety, tolerance and pharmacokinetics of SNC109 in patients with rGBM
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of SNC-109 CAR-T Cell Therapy in Subjects With Recurrent Glioblastoma
This is a single arm clinical study to estimate the safety, tolerability and pharmacokinetic (PK) characteristics of Chimeric Antigen Receptor-modified T cells (CAR-T) SNC-109 in patients with recurrent glioblastoma (r-GBM) and preliminarily evaluate the effectiveness, the immunogenicity of the product, as well as their correlation between the changes of cytokines from baseline level after cellular infusion.
100 Clinical Results associated with SNC-109
100 Translational Medicine associated with SNC-109
100 Patents (Medical) associated with SNC-109
100 Deals associated with SNC-109